Pfizer’s US Rituximab Launched At A 24% Discount

Trastuzumab Will Launch Next Month With A 22% Lower Price

 
• By David Wallace
Hands_Rockets
Pfizer will be the first firm to launch three oncology monoclonal antibody US biosimilars • Source: Shutterstock

More from Products

More from Generics Bulletin